CMS Signs a License Agreement with Zydus for Desidustat in Greater China

 CMS Signs a License Agreement with Zydus for Desidustat in Greater China

CMS Signs a License Agreement with Zydus for Desidustat in Greater China

Shots:

  • Zydus to receive up front, development & commercial milestones and royalties on sales of Desidustat while CMS to get a license to develop & commercialize the therapy for CKD patients in Greater China
  • The collaboration provides Zydus access to Greater China and facilitates the availability of Desidustat to the millions of CKD patients living with anemia
  •  Desidustat is a novel oral HIF-PH inhibitor, currently being evaluated in two P-III studies (DREAM-ND & DREAM-D) in non-dialysis & dialysis CKD patients respectively and had met 1EPs and showed good safety profile in its P-II studies

Click here ­to­ read full press release/ article | Ref: Zydus Cadila | Image: Asian Age

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post